PIM1 and hematologic disorder: For example, a gain-of-function mutation in PIM1, which encodes a kinase associated with the tumorigenesis of hematologic malignancies and is associated with resistance to BTK inhibitors, was observed in two patients resistant to the R2A regimen30.